13.32
6.53%
-0.93
Solid Biosciences Inc stock is currently priced at $13.32, with a 24-hour trading volume of 871.45K.
It has seen a -6.53% decreased in the last 24 hours and a +40.95% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $14.13 pivot point. If it approaches the $13.26 support level, significant changes may occur.
Solid Biosciences Inc Stock (SLDB) Financials Data
Solid Biosciences Inc (SLDB) Revenue 2022
SLDB reported a revenue (TTM) of $14.79 million for the quarter ending June 30, 2022.
Solid Biosciences Inc (SLDB) Net Income 2023
SLDB net income (TTM) was -$96.02 million for the quarter ending December 31, 2023, a -11.67% decrease year-over-year.
Solid Biosciences Inc (SLDB) Cash Flow 2023
SLDB recorded a free cash flow (TTM) of -$95.69 million for the quarter ending December 31, 2023, a +5.24% increase year-over-year.
Solid Biosciences Inc (SLDB) Earnings per Share 2023
SLDB earnings per share (TTM) was -$4.84 for the quarter ending December 31, 2023, a +52.03% growth year-over-year.
Solid Biosciences Inc Stock (SLDB) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
PERCEPTIVE ADVISORS LLC | Director |
Jan 11 '24 |
Buy |
5.53 |
3,410,713 |
18,861,243 |
6,833,539 |
RA CAPITAL MANAGEMENT, L.P. | Director |
Jan 11 '24 |
Buy |
5.53 |
904,160 |
5,000,005 |
4,192,216 |
Tan Kevin | CFO & Treasurer |
Jan 09 '24 |
Sale |
8.20 |
3,935 |
32,267 |
9,308 |
Ganot Ilan | Director |
Jan 03 '24 |
Sale |
5.30 |
1,142 |
6,052 |
8,167 |
Cumbo Alexander | President and CEO |
Dec 04 '23 |
Sale |
2.77 |
11,757 |
32,516 |
17,439 |
Howton David T | Chief Operating Officer |
Dec 04 '23 |
Sale |
2.78 |
5,367 |
14,920 |
7,684 |
Hanrahan Jessie | Chief Regulatory Officer |
Dec 04 '23 |
Sale |
2.78 |
4,879 |
13,562 |
6,983 |
Marlowe Jennifer | CSO |
Dec 04 '23 |
Sale |
2.77 |
4,890 |
13,525 |
6,998 |
Herzich Paul | Chief Technology Officer |
Dec 04 '23 |
Sale |
2.77 |
2,968 |
8,232 |
4,270 |
Ganot Ilan | Director |
May 02 '23 |
Sale |
4.85 |
487 |
2,364 |
4,153 |
Solid Biosciences Inc Stock (SLDB) Latest News
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
Benzinga
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
GlobeNewswire Inc.
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
Zacks Investment Research
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
Zacks Investment Research
Top 4 Health Care Stocks You May Want To Dump In February
Benzinga
Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
About Solid Biosciences Inc
Solid Biosciences Inc. engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation. In addition, it is developing soft wearable assistive devices that have functional and therapeutic benefits to DMD patients. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):